MARGINAL ZONE LYMPHOMA

This study tests whether adding two drugs (tafasitamab and lenalidomide) to standard rituximab helps people with relapsed follicular or marginal zone lymphoma live longer without their cancer growing. About 654 adults who have already tried at least one prior treatment will be ra…

This study tests a combination of two immunotherapy drugs, glofitamab and obinutuzumab, in 47 people with follicular lymphoma or marginal zone lymphoma who have not had prior treatment. The goal is to see how well the drugs control the cancer by measuring complete metabolic respo…

This phase 2 trial tests a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma (a slow-growing blood cancer). About 175 participants will receive the treatment to see if it improves complete response rates at 12 months and progressio…

This study tests a chemotherapy-free combination of two drugs, Copanlisib and Rituximab, in 36 people with marginal zone lymphoma (MZL) who need treatment but cannot have or have failed local therapy. The goal is to see if this combo works as well as standard chemo but with fewer…

This study tests a drug called obinutuzumab in 56 people with newly diagnosed marginal zone lymphoma who cannot have or did not respond to local therapy. The goal is to see if this antibody can shrink tumors and control the disease without the harsh side effects of chemotherapy. …

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have returned or not responded to prior treatments. The drug delivers radiation directly to cancer cells. A…

This study tests a combination of two drugs, acalabrutinib and tafasitamab, in about 26 people with marginal zone lymphoma that has come back after prior treatment. The goal is to see how well the drugs shrink tumors and to check for side effects. Participants receive treatment f…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing types of B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with various subtypes, including follicular lymphoma and chro…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study tests an experimental drug called epcoritamab in Japanese adults whose B-cell lymphoma has come back or not responded to treatment. The trial has two parts: first, finding a safe dose, and second, checking how well the drug works alone or with other treatments. About 7…

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with Richter's transformation or certain non-Hodgkin lymphomas. The goal is to find the safest dose and see how well the drugs work together. About 27 adults will take part, and the study…

This study follows about 50 people who have already received an experimental CAR T cell therapy for certain types of lymphoma. The goal is to track any long-term side effects and survival for up to 15 years after treatment. No new study drug is given, but participants may receive…

This study looks back at nearly 500 people with marginal zone lymphoma to see how well PET scans work for staging the disease and predicting how patients will do. Researchers will compare PET results with CT scans and other tests to see if PET provides extra useful information. T…